Key result
Relapsed synovial sarcoma in youth shows ~42% 5-year survival, with better outcomes linked to younger age.
Why the study?
Twenty-five to 32% of patients with synovial sarcoma relapse after appropriate treatment and experience poor outcomes, necessitating clearer identification of patients salvageable by second-line therapy.
Comparison
Treatment of relapse with surgery, second-line chemotherapy, and/or radiotherapy
Design
Retrospective cohort study
Follow-up
5 years
Authors
Loading...
Should not yet guide management in relapsed pediatric synovial sarcoma; hypothesis-generating and requires prospective validation.
Cohort (n=37)
Yes
Relapse of synovial sarcoma in children and adolescents remains curable in some cases, with better survival correlated with primary tumor involving limbs, age <12 at diagnosis, absence of initial chemo/radiotherapy, and local relapse.
Soole et al. (2014) conducted a cohort in Synovial sarcoma relapse (n=37). Relapse treatment and prognostic factors was evaluated on 5-year event-free survival and overall survival. In children and adolescents with relapsed synovial sarcoma, 5-year overall survival was 42.1%, with better survival correlated with age <12 years, limb tumors, and local relapse.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: